Cargando…
B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy
Defects in the apoptosis mechanism stimulate cancer cell growth and survival. B cell lymphoma 2 (Bcl-2) is an anti-apoptotic molecule that plays a central role in apoptosis. Bcl-2 is the founding constituent of the Bcl-2 protein family of apoptosis controllers, the primary apoptosis regulators linke...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509036/ https://www.ncbi.nlm.nih.gov/pubmed/34638779 http://dx.doi.org/10.3390/ijms221910442 |
_version_ | 1784582240000278528 |
---|---|
author | Alam, Manzar Ali, Sabeeha Mohammad, Taj Hasan, Gulam Mustafa Yadav, Dharmendra Kumar Hassan, Md. Imtaiyaz |
author_facet | Alam, Manzar Ali, Sabeeha Mohammad, Taj Hasan, Gulam Mustafa Yadav, Dharmendra Kumar Hassan, Md. Imtaiyaz |
author_sort | Alam, Manzar |
collection | PubMed |
description | Defects in the apoptosis mechanism stimulate cancer cell growth and survival. B cell lymphoma 2 (Bcl-2) is an anti-apoptotic molecule that plays a central role in apoptosis. Bcl-2 is the founding constituent of the Bcl-2 protein family of apoptosis controllers, the primary apoptosis regulators linked with cancer. Bcl-2 has been identified as being over-expressed in several cancers. Bcl-2 is induced by protein kinases and several signaling molecules which stimulate cancer development. Identifying the important function played by Bcl-2 in cancer progression and development, and treatment made it a target related to therapy for multiple cancers. Among the various strategies that have been proposed to block Bcl-2, BH3-mimetics have appeared as a novel group of compounds thanks to their favorable effects on many cancers within several clinical settings. Because of the fundamental function of Bcl-2 in the regulation of apoptosis, the Bcl-2 protein is a potent target for the development of novel anti-tumor treatments. Bcl-2 inhibitors have been used against several cancers and provide a pre-clinical platform for testing novel therapeutic drugs. Clinical trials of multiple investigational agents targeting Bcl-2 are ongoing. This review discusses the role of Bcl-2 in cancer development; it could be exploited as a potential target for developing novel therapeutic strategies to combat various types of cancers. We further highlight the therapeutic activity of Bcl-2 inhibitors and their implications for the therapeutic management of cancer. |
format | Online Article Text |
id | pubmed-8509036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85090362021-10-13 B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy Alam, Manzar Ali, Sabeeha Mohammad, Taj Hasan, Gulam Mustafa Yadav, Dharmendra Kumar Hassan, Md. Imtaiyaz Int J Mol Sci Review Defects in the apoptosis mechanism stimulate cancer cell growth and survival. B cell lymphoma 2 (Bcl-2) is an anti-apoptotic molecule that plays a central role in apoptosis. Bcl-2 is the founding constituent of the Bcl-2 protein family of apoptosis controllers, the primary apoptosis regulators linked with cancer. Bcl-2 has been identified as being over-expressed in several cancers. Bcl-2 is induced by protein kinases and several signaling molecules which stimulate cancer development. Identifying the important function played by Bcl-2 in cancer progression and development, and treatment made it a target related to therapy for multiple cancers. Among the various strategies that have been proposed to block Bcl-2, BH3-mimetics have appeared as a novel group of compounds thanks to their favorable effects on many cancers within several clinical settings. Because of the fundamental function of Bcl-2 in the regulation of apoptosis, the Bcl-2 protein is a potent target for the development of novel anti-tumor treatments. Bcl-2 inhibitors have been used against several cancers and provide a pre-clinical platform for testing novel therapeutic drugs. Clinical trials of multiple investigational agents targeting Bcl-2 are ongoing. This review discusses the role of Bcl-2 in cancer development; it could be exploited as a potential target for developing novel therapeutic strategies to combat various types of cancers. We further highlight the therapeutic activity of Bcl-2 inhibitors and their implications for the therapeutic management of cancer. MDPI 2021-09-28 /pmc/articles/PMC8509036/ /pubmed/34638779 http://dx.doi.org/10.3390/ijms221910442 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Alam, Manzar Ali, Sabeeha Mohammad, Taj Hasan, Gulam Mustafa Yadav, Dharmendra Kumar Hassan, Md. Imtaiyaz B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy |
title | B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy |
title_full | B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy |
title_fullStr | B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy |
title_full_unstemmed | B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy |
title_short | B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy |
title_sort | b cell lymphoma 2: a potential therapeutic target for cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509036/ https://www.ncbi.nlm.nih.gov/pubmed/34638779 http://dx.doi.org/10.3390/ijms221910442 |
work_keys_str_mv | AT alammanzar bcelllymphoma2apotentialtherapeutictargetforcancertherapy AT alisabeeha bcelllymphoma2apotentialtherapeutictargetforcancertherapy AT mohammadtaj bcelllymphoma2apotentialtherapeutictargetforcancertherapy AT hasangulammustafa bcelllymphoma2apotentialtherapeutictargetforcancertherapy AT yadavdharmendrakumar bcelllymphoma2apotentialtherapeutictargetforcancertherapy AT hassanmdimtaiyaz bcelllymphoma2apotentialtherapeutictargetforcancertherapy |